Tuesday, 06 September 2022 12:00

In-person event – venue MSG-024/25, Bernal Institute.

Tea/Coffee available in MSSi Social Space from 11h45


Oral administration of peptides – they said it couldn’t be done


These are exciting times for efforts to administer large molecules by the oral route, with two recent notable FDA approvals for peptides formulated in capsules or tablets for systemic delivery, plus numerous
peptides in trials for local delivery to the large intestine to treat IBD. Lest we get too carried away, the oral bioavailability of the former when formulated with traditional permeation enhancers is typically < 1% and
this means that such approaches will only work for potent peptides and ideally have a long half-life. The field is split between groups who favour this more conservative approach of matching payloads with a
particular established enhancer, and those who favour more radical approaches offered by device-based delivery, as well as nanotechnology. It has taken more than 40 years to get to this stage. Our group’s research on the mechanism of action of the intestinal permeation enhancers, sodium caprate, SNAC, and Labrasol™ has contributed to the clinical development of several peptide products that are administered
orally. I will discuss our efforts to decipher their actions in different bioassays as well as our more recent work using a core-silica shell nanoparticle to entrap peptides.


Full Professor of Advanced Drug Delivery at the School of Veterinary Medicine, University College Dublin (UCD) and also a Senior Fellow of the UCD Conway Institute of Biotechnology. Following a Ph.D. in
Pharmacology at the University of Cambridge, UK (1989), and a post-doctoral research fellowship at Stanford University, CA, he set up Elan Biotechnology Research’s in vitro pharmacology laboratory in
Dublin (1991). At Elan, he became a senior scientist and was project manager of several of Elan’s Joint Venture drug delivery research collaborations with US biotech companies. In 2001, he joined UCD as a
lecturer in veterinary pharmacology and was appointed Full Professor in 2014. He was the Director of the Science Foundation Ireland (SFI) Research Cluster (The Irish Drug Delivery Research Network) from
2007-2013, Deputy Coordinator of an FP7 Consortium on oral peptides in nanoparticles (“TRANS-INT”, 2012-2017), and is currently a Co-Lead Principal Investigator in “CURAM”, SFI’s Centre for Medical Devices
(2021-2026, www.curamdevices.ie) and Coordinator of a new Horizon consortium project, BUCCAL-PEP (2022-2026). He was made a Fellow of the Controlled Release Society in 2012 and was also elected as a
Fellow of the American Association of Pharmaceutical Scientists (2017). He is the author or co-author of more than 300 research publications and patents. David was appointed Chief Editor of Frontiers in Drug
Delivery in 2021. He serves on the Editorial Advisory Boards of Drug Discovery Today, Advanced Drug Delivery Reviews and the Journal of Veterinary Pharmacology and Therapeutics. In 2021, he was
appointed by the Minister of Health to Ireland’s National Research Ethics Committee (Clinical Trials A). His current research is in oral and buccal delivery of macromolecules using nanoparticles and permeation
enhancers, as well as intra-articular delivery of nanoparticles to treat arthritis.

Contact: david.brayden@ucd.ie

For further information, please contact: edmond.magner@ul.ie